_ _ _ 6% for propranolol plus sclerotherapy and 59% +_ 6% for propranolol alone (a nonsignificant difference). Twenty-eight patients from the propranolol group but only 12 patients from the propranoloi-plus-sclerotherapy group had recurrent bleeding from esophageal variceal rupture (p < 0.01). The total number of blood units per patient with recurrent bleeding was slightly but not significantly more important in the propranolol group (8 __+ 7) than in the propranoloi-plus-sclerotherapy group (5 _ _ _ 5; p--0.09). There were no statistical differences in the cumulative survival rate at 2 yr (propranolol plus sclerotherapy, 74% __+ 6% and propranolol alone, 64% __+ 6%) or in the number of patients who died of repeat bleeding (propranolol plus sclerotherapy, 13% __+ 4% and propranolol alone, 17% + 5%). Among the surviving patients, cirrhosis
We conducted a prospective, multicenter, randomized trial to compare the efficacy of sclerotherapy plus propranolol with that of propranoloi alone in the prevention of recurrent gastroesophageal bleeding in severely cirrhotic patients. For 2 yr (1987 to 1988) 131 patients (96% of whom were alcoholic) with Child-Pugh class B or C cirrhosis (56% were class B and 44% were class C) were randomly assigned to one of our two treatment groups after cessation of variceal bleeding, without hernostatic sclerosis, and were observed for at least 2 yr. Treatment observance was good in 89% of cases; alcohol withdrawal was observed in 62% of cases. Sclerotherapy was performed weekly with 1% polidocanol, and variceal obliteration was obtained in 83% of cases, in a mean number of four sessions. "lhe cumulative percentages (expressed as mean __+ S.D.) of recurrent bleeding at 2 yr were 42% _ _ _ 6% for propranolol plus sclerotherapy and 59% +_ 6% for propranolol alone (a nonsignificant difference). Twenty-eight patients from the propranolol group but only 12 patients from the propranoloi-plus-sclerotherapy group had recurrent bleeding from esophageal variceal rupture (p < 0.01). The 
